Alexei Kharitonenkov

From Wikitia
Jump to navigation Jump to search
Alexei Kharitonenkov
Add a Photo
NationalityRussian-American
CitizenshipUnited States of America
OccupationResearcher

Alexei Kharitonenkov (Russian: Алексей Игоревич Харитоненков) is a Russian-American researcher best known for his discoveries of endocrine functions of Fibroblast Growth Factor 21 (FGF21) and its prospects in developing novel therapies for metabolic diseases.[1] Likewise, his lines of study on the structure and functions of Signal-Regulatory Proteins (SIRPs),[2] and on protein-tyrosine phosphatases,[3] and their roles in the pathophysiology of cancer have been highlighted by reviewers in the corresponding fields.[4][5][6][7]

Education

In 1985, Kharitonenkov graduated with a MS in Physics from Moscow State University (MSU), Moscow, Russia.[8] In 1990, he received a PhD degree in Biochemistry from MSU,[9] followed by post-doctoral fellowship trainings in molecular biology and signal transduction at Max-Planck-Institute for Biochemistry, Martinsried, Germany (1992-1994).[10]

Career

Since 1986 to 1992 he was a research fellow at Biochemistry Department, Biology Faculty, Moscow State University, Moscow, Russia.[8][9][11] Between 1994–1998 he was a staff scientist at the Molecular Biology department of Max-Planck-Institute for Biochemistry, Martinsried, Germany.[2][10][12][13][14][15] He joined Eli Lilly and Company until 2014,[16] when he moved to Calibrium; LLC;[17] upon acquisition of this company,[18] he joined Novo Nordisk USA in 2016.[19][20] More recently, Kharitonenkov has been an executive and/or founder of startups within the biopharmaceutical field, [21][22] where he has also been an inventor.[23]

He has authored more than 100 peer reviewed papers, most of them studying aspects of signal transduction, molecular biology, pharmacology, drug discovery and development in the areas of cancer and metabolic diseases.[24] He is also a contributing author to chapters of review books on endocrine FGFs and metabolism,[25] and FGF21 as a therapeutic agent.[26] In 1997 and 2005 he contributed to priming articles describing structures and functions of SIRPs [2] and FGF21.[27]

Works

Kharitonenkov's research papers have been cited over 14,500 times.[28]

According to Google Scholar,[24] his most cited papers are:

  • Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li D-S, Mehrbod F, Jaskunas SR, and Shanafelt AB. "FGF-21 as a novel metabolic regulator". J. Clin. Invest. 115:1627-35 (2005) doi:10.1172/JCI23606. PMID 15902306

References

  1. ↑ Seaborg, Eric (2013-04-01). "Metabolic Breakthrough". Endocrine News. Retrieved 2022-11-13.
  2. ↑ 2.0 2.1 2.2 Kharitonenkov, A.; Chen, Z.; Sures, I.; Wang, H.; Schilling, J.; Ullrich, A. (1997-03-13). "A family of proteins that inhibit signalling through tyrosine kinase receptors". Nature. 386 (6621): 181–186. doi:10.1038/386181a0. ISSN 0028-0836. PMID 9062191.
  3. ↑ "Google Scholar". scholar.google.es. Retrieved 2022-11-13.
  4. ↑ Cambier, J. C. (1997-06-10). "Inhibitory receptors abound?". Proceedings of the National Academy of Sciences of the United States of America. 94 (12): 5993–5995. doi:10.1073/pnas.94.12.5993. ISSN 0027-8424. PMC 33673. PMID 9177155.
  5. ↑ Lai, Lisa A.; Zhao, Chunmei; Zhang, Eric E.; Feng, Gen-Sheng (2004), Ariño, Joaquí n; Alexander, Denis R. (eds.), "The Shp-2 tyrosine phosphatase", Protein Phosphatases, Berlin, Heidelberg: Springer Berlin Heidelberg, vol. 5, pp. 275–299, doi:10.1007/978-3-540-40035-6_14, ISBN 978-3-540-20560-9, retrieved 2022-11-13
  6. ↑ Hendriks, Wiljan J. A. J.; Böhmer, Frank-D (2016), Neel, Benjamin G.; Tonks, Nicholas K. (eds.), "Non-transmembrane PTPs in Cancer", Protein Tyrosine Phosphatases in Cancer, New York, NY: Springer New York, pp. 47–113, doi:10.1007/978-1-4939-3649-6_3, ISBN 978-1-4939-3647-2, retrieved 2022-11-13
  7. ↑ Bence, Kendra K. (2016), Neel, Benjamin G.; Tonks, Nicholas K. (eds.), "Protein-Tyrosine Phosphatases: Linking Metabolism and Cancer", Protein Tyrosine Phosphatases in Cancer, New York, NY: Springer New York, pp. 307–333, doi:10.1007/978-1-4939-3649-6_12, ISBN 978-1-4939-3647-2, retrieved 2022-11-13
  8. ↑ 8.0 8.1 Kharitonenkov, A. I.; Kudriavtseva, N. G.; Bulargina, T. V. (1989-10-01). "[Preparation of monoclonal antibodies to phosphotyrosine and their use for identification of phosphotyrosine-containing proteins]". Biokhimiia (Moscow, Russia). 54 (10): 1732–1739. ISSN 0320-9725. PMID 2481508.
  9. ↑ 9.0 9.1 Kharitonenkov, A. I.; Bulargina, T. V. (1991-02-01). "[Autophosphorylation of EGF receptors in the A431 cell line with an increased intracellular concentration of Ca(2+) ions]". Biokhimiia (Moscow, Russia). 56 (2): 374–382. ISSN 0320-9725. PMID 1873350.
  10. ↑ 10.0 10.1 Møller, N. P.; Møller, K. B.; Lammers, R.; Kharitonenkov, A.; Sures, I.; Ullrich, A. (1994-08-02). "Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain". Proceedings of the National Academy of Sciences of the United States of America. 91 (16): 7477–7481. doi:10.1073/pnas.91.16.7477. ISSN 0027-8424. PMC 44424. PMID 7519780.
  11. ↑ Kharitonenkov, A. I.; Bulgarina, T. V. (1990-06-01). "[The effect of phorbol esters and Ca2+ ions on the process of autophosphorylation of epidermal growth factor receptor in vivo]". Biokhimiia (Moscow, Russia). 55 (6): 1104–1109. ISSN 0320-9725. PMID 2207207.
  12. ↑ Møller, N. P.; Møller, K. B.; Lammers, R.; Kharitonenkov, A.; Hoppe, E.; Wiberg, F. C.; Sures, I.; Ullrich, A. (1995-09-29). "Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatases alpha and epsilon". The Journal of Biological Chemistry. 270 (39): 23126–23131. doi:10.1074/jbc.270.39.23126. ISSN 0021-9258. PMID 7559456.
  13. ↑ Stein-Gerlach, M.; Kharitonenkov, A.; Vogel, W.; Ali, S.; Ullrich, A. (1995-10-20). "Protein-tyrosine phosphatase 1D modulates its own state of tyrosine phosphorylation". The Journal of Biological Chemistry. 270 (42): 24635–24637. doi:10.1074/jbc.270.42.24635. ISSN 0021-9258. PMID 7559570.
  14. ↑ Kharitonenkov, A.; Schnekenburger, J.; Chen, Z.; Knyazev, P.; Ali, S.; Zwick, E.; White, M.; Ullrich, A. (1995-12-08). "Adapter function of protein-tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate-1 interaction". The Journal of Biological Chemistry. 270 (49): 29189–29193. doi:10.1074/jbc.270.49.29189. ISSN 0021-9258. PMID 7493946.
  15. ↑ Ali, S.; Chen, Z.; Lebrun, J. J.; Vogel, W.; Kharitonenkov, A.; Kelly, P. A.; Ullrich, A. (1996-01-02). "PTP1D is a positive regulator of the prolactin signal leading to beta-casein promoter activation". The EMBO Journal. 15 (1): 135–142. doi:10.1002/j.1460-2075.1996.tb00341.x. ISSN 0261-4189. PMC 449925. PMID 8598196.
  16. ↑ Kharitonenkov, Alexei; Adams, Andrew C. (2014-06-01). "Inventing new medicines: The FGF21 story". Molecular Metabolism. 3 (3): 221–229. doi:10.1016/j.molmet.2013.12.003. ISSN 2212-8778. PMC 3986619. PMID 24749049.
  17. ↑ Kharitonenkov, Alexei; DiMarchi, Richard (2015-11-01). "FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties". Trends in Endocrinology and Metabolism: TEM. 26 (11): 608–617. doi:10.1016/j.tem.2015.09.007. ISSN 1879-3061. PMID 26490383.
  18. ↑ Taylor, Nick Paul (2015-08-28). "Novo Nordisk buys diabetes startups founded by Lilly R&D veteran". Fierce Biotech. Retrieved 2022-12-01.
  19. ↑ Agrawal, Archita; Parlee, Sebastian; Perez-Tilve, Diego; Li, Pengyun; Pan, Jia; Mroz, Piotr A.; Kruse Hansen, Ann Maria; Andersen, Birgitte; Finan, Brian; Kharitonenkov, Alexei; DiMarchi, Richard D. (2018-07-01). "Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity". Molecular Metabolism. 13: 45–55. doi:10.1016/j.molmet.2018.05.003. ISSN 2212-8778. PMC 6026317. PMID 29789271.
  20. ↑ Pan, Jia; Parlee, Sebastian D.; Brunel, Florence M.; Li, Pengyun; Lu, Wei; Perez-Tilve, Diego; Liu, Fa; Finan, Brian; Kharitonenkov, Alexei; DiMarchi, Richard D. (2020-10-09). "Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21". ACS Pharmacology & Translational Science. 3 (5): 978–986. doi:10.1021/acsptsci.0c00100. ISSN 2575-9108. PMC 7551714. PMID 33073195.
  21. ↑ "News and events". Alpha Young. Retrieved 2022-12-01.
  22. ↑ "Biotech Consulting | AKbiotech". AK biotechnologies. Retrieved 2022-12-01.
  23. ↑ "Alexei Kharitonenkov Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2022-11-28.
  24. ↑ 24.0 24.1 "Google Scholar". scholar.google.es. Retrieved 2022-12-01.
  25. ↑ Micanovic, Radmila; Dunbar, James D.; Kharitonenkov, Alexei (2011-04-08), Wang, Minghan (ed.), "Fibroblast Growth Factor 21 as a Novel Metabolic Regulator", Metabolic Syndrome, Hoboken, NJ, USA: John Wiley & Sons, Inc., pp. 377–389, doi:10.1002/9780470910016.ch14, ISBN 978-0-470-91001-6, retrieved 2022-11-28
  26. ↑ Zhao, Yang; Dunbar, James D.; Kharitonenkov, Alexei (2012), Kuro-o, Makoto (ed.), "FGF21 as a Therapeutic Reagent", Endocrine FGFs and Klothos, New York, NY: Springer US, vol. 728, pp. 214–228, doi:10.1007/978-1-4614-0887-1_14, ISBN 978-1-4614-0886-4, retrieved 2022-11-28
  27. ↑ Kharitonenkov, Alexei; Shiyanova, Tatiyana L.; Koester, Anja; Ford, Amy M.; Micanovic, Radmila; Galbreath, Elizabeth J.; Sandusky, George E.; Hammond, Lisa J.; Moyers, Julie S.; Owens, Rebecca A.; Gromada, Jesper; Brozinick, Joseph T.; Hawkins, Eric D.; Wroblewski, Victor J.; Li, De-Shan (2005-06-01). "FGF-21 as a novel metabolic regulator". The Journal of Clinical Investigation. 115 (6): 1627–1635. doi:10.1172/JCI23606. ISSN 0021-9738. PMC 1088017. PMID 15902306.
  28. ↑ "Alexei Kharitonenkov". Researchgate.

External links

Add External links

This article "Alexei Kharitonenkov" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.

Retrieved from "https://wikitia.com/index.php?title=Alexei_Kharitonenkov&oldid=163497"